Studies were performed to identify factors explaining the difference in the
neurodegeneration seen in Alzheimer’s disease (AD) and in transgenic mice. A high level of
neuronal loss is typically associated with AD, whereas in transgenic mice, this feature is only
weakly displayed. Furthermore, the studies aimed at determining proteins occurring at altered
levels in AD brains which could be involved in pathogenic mechanisms underlying the disease.
The results of these investigations could help to identify Aβ variants and other proteins affecting
the degree of neurodegeneration and would hopefully contribute to the development of
biomarkers and new drug targets in AD.
Using laser dissection microscopy in combination with MALDI-TOF MS and urea-based
Western blotting, the Aβ composition in morphologically differentiated plaque types from three
different sources could be investigated: human brains from AD patients, pathologically aging
(PA) individuals – i.e. individuals who form amyloid plaques, but suffer of no cognitive
impairment - and from double-transgenic PS2APP mice. Diffuse plaques are found in human AD
and PA, as well as in PS2APP transgenic mice and were previously suggested to be the initially
occurring plaque type. We detected almost exclusively Aβ 42 in diffuse plaques. This Aβ variant
was shown to be prone to aggregation. Furthermore, no differences in the Aβ species
composition between diffuse plaques from AD and PA individuals were detected. Cored plaques,
the main plaque type in AD, contain also predominantly Aβ 42, whereas compact plaques, which
sporadically occur in human but are found more frequently in PS2APP mice, consist of Aβ 40.
This has implications on the putative evolutionary path of plaque formation: Due to the Aβ
composition of the respective plaque types, a sequential maturation of diffuse plaques over
compact to cored plaques can be excluded. Our data support the concept that diffuse plaques are
the initially occurring plaque type and develop independently to compact or cored plaques. The
Aβ composition of vascular amyloid was also investigated. Here, we detected high amounts of
Aβ 40, which is consistent with previous findings using C-terminal specific antibodies.
Aβ in human plaques and to a considerably lesser extent in plaques from PS2APP mice is
N-terminally truncated. The investigation of different Braak stages revealed an increasing
amount of N-terminally truncated Aβ variants accompanying disease progression, indicative for
a successive modification by exoproteases upon deposition. Consistently low levels of Nterminally
truncated Aβ forms were detected in diffuse plaques, which further support the view
of diffuse plaques being at the beginning of the plaque maturation process. The major Nterminally
truncated Aβ variant detected by MALDI-TOF MS in human cored plaques was
pyroglutamate 3-40 / 42. To corroborate these findings, Western blotting and immunohistochemistry
were applied and the existence of pyroglutamate in all types of plaques in human
AD and PS2APP transgenic mice was shown.
The rate of aggregation of an Aβ variant is likely to be important for initial deposition of
amyloid into plaques. To test the aggregation and toxicity properties of pyroglutamate 3-42, in
vitro experiments were performed on PC12 and hippocampal cell lines comparing synthetic
pyroglutamate 3-42 with Aβ 1-42. These experiments showed a considerably lower rate of
aggregation for synthetic pyroglutamate 3-42 when compared to Aβ 1-42. Our experiments
suggest that pyroglutamate 3-40 / 42 alone is probably not a critical seed for plaque formation.
The cytotoxicity of Aβ peptides is correlated with the aggregation state. Synthetic pyroglutamate
3-42 in vitro showed a significantly reduced toxicity when compared to Aβ 1-42.
Cross-linking of Aβ fibrils in plaques was investigated with solubility experiments. It was
found that Aβ in human plaques is cross-linked to a higher extent than Aβ in plaques from
PS2APP transgenic mice. A higher degree of cross-linking in human Aβ was also indicated by
our MALDI-TOF MS analysis. The high level of cross-linking may result in a hampered
clearance of Aβ from the brain in AD patients. Taken together, enhanced levels of posttranslational
modifications in human plaques, i.e. cross-linking and N-terminal truncation of Aβ
peptides, may lead to their reduced clearance from the brain.
The methodology used in our experiments allowed to discriminate between oxidized and
reduced Aβ species. Diffuse plaques in PA were shown to contain a large proportion of oxidized
Aβ, which could indicate a protective response in these brains and which would explain the lack
of clinical symptoms in these individuals.
To determine, whether the amyloid load in plaques may contribute to the high level of
neuronal loss observed in AD as opposed to transgenic PS2APP mice, 15N-labeled Aβ 1-42 was
used and the quantitative amyloid load in plaques from human AD and PS2APP mice was
compared by MALDI-TOF MS. Roughly comparable amounts of Aβ in both species were found.
Therefore, we conclude that a dose-effect of Aβ alone can not account for the higher level of
neurodegeneration observed in AD patients than in PS2APP mice.
Using LC/MS/MS the identification of additional proteins involved or affected in the
pathogenesis of AD was aimed at. A comparison of the proteome in AD brain with control tissue
was based on the analysis of over 2000 proteins. Proteins generally accepted to be related to AD
like Aβ, apolipoprotein E, heat shock protein 90, glial fibrillary acidic protein (GFAP) and tau
were detected at increased levels in AD. Numerous proteins previously tentatively implicated
with the disease were identified at aberrant levels in AD. We found proteins indicative for an
enhanced susceptibility to oxidative stress (e.g. decrease of peroxiredoxin 5), an impaired
glucose metabolism (decrease of enzymes involved in citrate cycle), cytoskeletal derangement
(e.g. decrease in alpha-internexin), synaptic dysfunction (e.g. decrease in presynaptic density
protein-95, syntaxin-1A and synaptotagmin-1), an activation of the ubiquitin proteasome system
(increase in ubiquitin), deficits in the neuritic network (decrease of various cell adhesion
molecules) and membrane trafficking (e.g. decrease in AP-180), as well as altered levels of
enzymes involved in the hyperphosphorylation of tau (e.g. decrease in phosphatase-2A).
Most notably, we detected 18 new proteins previously not associated with the disease,
which occurred at altered levels in AD. These are the synaptic proteins synaptogyrin-1 and -3,
myelin associated glycoprotein, myelin oligodendrocyte glycoprotein, contactin-1, contactin-2,
neurexin IV and claudin-11 involved in cell adhesion, the chaperone protein Hsp 75, plectin 1,
ankyrin, α-adducin and microtubule-associated protein RP/EB family member 3 as structural
cytoskeletal proteins, peroxiredoxin 5 and microsomal glutathione S-transferase 3 for the
protection against oxidative stress and programmed cell death protein 8, matrin-3 and transgelin-
3, whose functions are not known. The findings obtained by LC/MS/MS were confirmed by
immunohistochemistry and Western blotting for selected proteins, thereby providing a first
validation of some of the proteins found at aberrant levels in AD. Interestingly, we were able to
authenticate decreased levels of syntaxin-1A and reticulon-1 and increased synaptogyrin-1 levels
in AD using confocal microscopy.
The identification of proteins involved in the processes finally leading to
neurodegeneration and cognitive deficits associated with AD could lead to the development of
biological markers for the disease. Such biomarker candidates found at altered levels in AD brain
tissue could possibly be reflected in the cerebrospinal fluid (CSF) and eventually in the periphery
and may be explored for their value as drug targets or markers for diagnosis, disease progression
or even responsiveness to treatment. The results from our studies indicate pathways which
appear promising in such a quest
